On Hump Day, investors piled into CRISPR Therapeutics (NASDAQ: CRSP) stock, sending its price more than 9% higher at the trading session's close. They were highly encouraged by the specialized ...

Why are CRISPR companies not OK? Will Robert F. Kennedy Jr. keep his promises if he's confirmed to lead the Department of ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR is hard to do profitably.

CRISPR technology has radically transformed genetic research, and at the forefront of this transformation is CRISPR screening ...

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will ...

Complementary discoveries have the potential to enhance treatment options for antibiotic-resistant infections. Researchers at ...

Using CRISPR technology, scientists uncovered genes that control C-A-G genetic stumbles in Huntington's disease ...

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

New gene therapy modalities, such as CRISPR guide RNA (single guide ribonucleic acid [sgRNA]) and messenger RNA (mRNA), ...

Why are CRISPR companies not OK? Will Robert F. Kennedy Jr. keep his promises if he’s confirmed to lead the Department of Health and Human Services? And how do you pronounce Journavx?